Han Jennifer H, Harmoney Kathryn M, Dokmeci Elif, Torrez Jacqueline, Chavez Cathy M, Cordova de Ortega Loretta, Kuttesch John F, Muller Martha, Winter Stuart S
Department of Pediatrics, The University of New Mexico Health Sciences Center, 1 University of New Mexico, Albuquerque, New Mexico, United States of America.
Department of Pediatrics, Division of Hematology/Oncology, University of Iowa Stead Family Children's Hospital, 200 Hawkins Drive, Iowa City, Iowa, United States of America.
PLoS One. 2018 Feb 1;13(2):e0191804. doi: 10.1371/journal.pone.0191804. eCollection 2018.
There are no universally approved re-vaccination guidelines for non-transplant pediatric cancer survivors. We hypothesized that by utilizing a response-based re-vaccination schedule, we could tailor vaccine schedules in off-treatment cancer survivors. Pre-vaccination antibody levels were obtained in 7 patients at an average of 20 days after the end of treatment date. In those without protective antibody levels, we administered vaccines 3 months after completion of treatment. Revaccinating patients 3 months after the end of treatment date resulted in protective antibody levels for most vaccines. We showed, on a preliminary basis, that vaccinating non-transplanted pediatric cancer survivors can be dynamically implemented in children with recovering immune function.
对于非移植的儿科癌症幸存者,目前尚无普遍认可的再次接种疫苗指南。我们假设,通过采用基于反应的再次接种疫苗时间表,可以为结束治疗的癌症幸存者量身定制疫苗接种计划。在7名患者中,于治疗结束日期后平均20天检测了接种前抗体水平。对于那些没有保护性抗体水平的患者,我们在治疗完成后3个月接种了疫苗。在治疗结束日期后3个月为患者再次接种疫苗,大多数疫苗都产生了保护性抗体水平。我们初步表明,对于免疫功能正在恢复的儿童,可以动态实施对未移植的儿科癌症幸存者进行疫苗接种。